Overview of Blood Coagulation
1Division of Hematology/Oncology, Department of Medicine, Northwestern University Medical School, Chicago, Illinois, U.S.A.
The endothelium is the principal anti-thrombotic mechanism, providing a non wettable surface and generating potent vasodilators (nitric oxide and prostacyclin) and clotting inhibitors [thrombomodulin and tissue factor pathway inhibitor (TFPI)]. When the integrity of the endothelium is breached, vasoconstriction occurs through neural and chemical (endothelin, thromboxane) mechanisms, and platelet adhesion is facilitated (von Willebrand factor). Activation of platelets accompanied by microparticle formation provides a thrombogenic surface for subsequent coagulation reactions. The initial generation of small amounts of thrombin greatly amplifies subsequent clotting factor activation and results in substantial thrombin formation. Thrombin activates an inhibitor of fibrinolysis [thrombin activatable fibrinolysis inhibitor (TAFI)] which prevents the binding of plasminogen to fibrin. Mechanisms to limit clot formation include inhibition of the tissue factor-factor VIIa complex by TFPI, inhibition of activated factors V and VIII by activated protein C, and binding of thrombin by thrombomodulin, heparin cofactor II, and anti-thrombin. Clot dissolution is promoted by plasminogen activators (tissue plasminogen activator and urokinase) and by plasminogen.
The endothelium is the principal anti-thrombotic mechanism, providing a non wettable surface and generating potent vasodilators (nitric oxide and prostacyclin) and clotting inhibitors [thrombomodulin and tissue factor pathway inhibitor (TFPI)]. When the integrity of the endothelium is breached, vasoconstriction occurs through neural and chemical (endothelin, thromboxane) mechanisms, and platelet adhesion is facilitated (von Willebrand factor). Activation of platelets accompanied by microparticle formation provides a thrombogenic surface for subsequent coagulation reactions. The initial generation of small amounts of thrombin greatly amplifies subsequent clotting factor activation and results in substantial thrombin formation. Thrombin activates an inhibitor of fibrinolysis [thrombin activatable fibrinolysis inhibitor (TAFI)] which prevents the binding of plasminogen to fibrin. Mechanisms to limit clot formation include inhibition of the tissue factor-factor VIIa complex by TFPI, inhibition of activated factors V and VIII by activated protein C, and binding of thrombin by thrombomodulin, heparin cofactor II, and anti-thrombin. Clot dissolution is promoted by plasminogen activators (tissue plasminogen activator and urokinase) and by plasminogen.
More Related Videos
09:19In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
04:37Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
Related Concept Videos
Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Coagulation
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
